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ABSTRACT
The identification of diagnostic and prognostic biomarkers from early lesions, 
measurable in liquid biopsies remains a major challenge, particularly in oncology. 
Fresh human material of high quality is required for biomarker discovery but is often 
not available when it is totally required for clinical pathology investigation. Hence, all 
OMICs studies are done on residual and less clinically relevant biological samples. Here 
after, we present an innovative, simple, and non-destructive, procedure named EXPEL 
that uses rapid, pressure-assisted, interstitial fluid extrusion, preserving the specimen 
for full routine clinical pathology investigation. In the meantime, the technique allows 
a comprehensive OMICs analysis (proteins, metabolites, miRNAs and DNA). As proof 
of concept, we have applied EXPEL on freshly collected human colorectal cancer and 
liver metastases tissues. We demonstrate that the procedure efficiently allows the 
extraction, within a few minutes, of a wide variety of biomolecules holding diagnostic 
and prognostic potential while keeping both tissue morphology and antigenicity 
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unaltered. Our method enables, for the first time, both clinicians and scientists to 
explore identical clinical material regardless of its origin and size, which has a major 
positive impact on translation to the clinic.
INTRODUCTION
Biomarkers readily detectable in liquid biopsies 
are of utmost importance for any healthcare system, in 
particular for diagnostic and therapeutic applications. 
This is particularly the case in oncology. The development 
of high throughput technologies able to perform 
comprehensive analysis of genes, transcripts, proteins 
and other significant biological molecules has provided 
an unprecedented opportunity for the identification 
of markers of disease processes [1]. Nevertheless, the 
number of biomarkers approved by the FDA remains 
modest [2]. Identification of pertinent OMIC biomarkers 
relies essentially on the availability of patient material 
ideally collected at different stages of tumour development 
(e.g. early lesion, before treatment and after recurrence). 
A major limitation for the discovery of such biomarkers 
is the inaccessibility of tissue material of interest. Indeed, 
to this day, it is virtually impossible to access fresh 
biopsies from pre- or early malignant lesions, as they are 
required in their entirety for pathological evaluation and 
diagnosis. The use of liquid biopsies (e.g. serum, urine, 
saliva) brought the promise to circumvent this problem, 
opening access to many different entities like circulating 
DNA, exosomes (containing miRNAs), proteins and 
metabolites. Indeed, upon their release from the tumour 
these molecules are diluted up to several billion-fold 
in blood where they are mixed with species originating 
from healthy tissues. A “blanket of noise” precludes 
straightforward analysis and even detection of relevant 
molecules, covering the biomarkers that would be useful 
in diagnosing and understanding the disease.
To overcome these difficulties, researchers have 
focused on tissue interstitial fluid, mainly used for 
proteomic analysis [3–8]. The available procedures, 
principally consist in incubating the tissue biopsy 
in serum-free culture medium for several hours and 
collecting the liquid and/or in collecting the supernatant 
after a low speed tissue centrifugation [7]. Both methods, 
although simple to perform, expose the tissues to long 
incubations (frequently overnight), which could favour 
the degradation of diagnostic markers epitopes by 
endogenous proteolytic enzymes and/or damage the 
histological architecture. Further to these common and 
simple methods, more sophisticated approaches based on 
microdialysis [9] and capillary ultrafiltration exist [10, 11]. 
They offer the possibility to collect interstitial fluid in vivo 
and in vitro but necessitate implantation of the probe in the 
tissue, most probably leading to distortion of histology. 
Importantly, none of these methods have ever been 
evaluated for their compatibility to be integrated in clinical 
workflow. Consequently, the key problem precluding 
access to precious tissues that need to be preserved for 
clinical/histological investigation and diagnosis remains 
unsolved and represents a major drawback for the 
identification of clinically relevant biomarkers.
We have developed a simple and original proximal 
tissue fluid mining method we named EXPEL. It enables 
efficient extraction of soluble biomarkers while conserving 
the tissue intact for subsequent pathological analysis. 
Importantly, the EXPEL method will not only allow the 
researchers to access human tissues that are very difficult 
to obtain, but for the first time, scientists and clinicians can 
share the same material for both experimental research and 
routine clinical analysis. The emphasis is further laid on 
the possibility to extract with this method a rich collection 
of biomolecules such as proteins, metabolites, miRNAs, 
DNA as well as small vesicles like exosomes. Now, all 
these moieties are routinely mined for clinical biomarkers 
aiming at therapeutic and diagnostic applications. An ideal 
methodology should be rapid to prevent degradation, yet 
remains comprehensive to extract various molecules in 
sufficient quantities. We hypothesised that subjecting 
tissue biopsies to cycles of low-pressure pulses under 
mild hypertonic conditions would allow a rapid extrusion 
of interstitial fluid containing the biomarkers of interest, 
while preserving the morphology and antigenicity of 
the sample for subsequent pathological investigation. 
To test the value of the EXPEL method we have applied 
our procedure to a series of primary colorectal tumours 
(CRC) and liver metastasis samples (CRC-LM). This 
proof-of-principle study demonstrates the validity of 
EXPEL-extruded fluid as unique starting material for the 
most advanced OMICs methodologies, while showing 
no disadvantage for routine clinical and pathological 
investigations.
RESULTS
The EXPEL method does not alter tissue 
morphology and antigenicity
To assure that the EXPEL methodology does not 
alter the morphology and antigenicity of fresh tissue 
biopsies, we have conducted a comparative analysis of 
various human and mouse tissues subjected to EXPEL 
method and standard pathological procedures. For this 
purpose, we have collected and processed different 
mouse organs. Each tissue sample was divided into two 
parts: i) for routine pathological analysis, and ii) for 
EXPEL processing. A similar workflow was then applied 
on human breast cancer, colorectal primary tumour and 
colon cancer liver metastases, together with their adjacent 
normal counterparts. The routine and EXPEL samples 
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were then subjected to common histology procedures 
(hematoxylin/eosin) and clinically relevant biomarkers 
immunodetection. IHC has been conducted using an 
automated staining platform and three independent 
pathologists have evaluated stained slides as described 
under Material and Methods. As displayed in Figure 1 and 
Supplementary Figure 1, no significant differences were 
found regarding the tissue structures (H&E) and staining 
intensities of the selected markers between EXPEL 
processing and standard pathological sampling method 
for all analysed human and mouse samples.
The EXPEL methodology allows the 
identification of protein biomarkers
EXPEL-extruded fluids were collected from 7 
colon cancer and 6 liver metastases patients with their 
corresponding normal tissue counterparts. They were 
processed for proteome analysis using UPLC-MS/MS 
methodology. Due to a difference in complexity, EXPEL 
fluids derived from colorectal samples were processed 
using 1D-LC-MS/MS analysis, while those originating 
from liver metastases were analysed using 2D-LC-MX/
MS. Over 2000 and 3000 proteins were identified for 
colon- and liver- extruded fluids respectively. To obtain 
an overview of the EXPEL-extruded fluid protein 
datasets, hierarchical clustering followed by Spearman 
Rank Correlation was performed using the LFQ (label 
free quantification, see material and methods) values for 
both colon and liver samples. Interestingly, as shown in 
Supplementary Figure 2, the general trend is that EXPEL 
fluids from the normal samples cluster separately from 
the tumoural ones. Exceptions to this trend were mainly 
found in the colon tissues datasets, a result that could be 
ascribable to the complex cellular composition of these 
tissues. To narrow down the list of potential biomarkers, 
we have further considered only proteins consistently 
identified in at least 4 out of 7 colon- and 3 out of 6 liver- 
EXPEL-extruded fluids (Figure 2A upper panel, left 
for CRC and right for CRC-LM). To gain insight in the 
predicted subcellular localisation of the identified proteins, 
we have interrogated STRING database (http://string-db.
org). Interestingly, we found that the subset of proteins 
located in the extracellular space was consistently more 
abundant in comparison with the number of proteins found 
in other cellular compartments (Figure 2A upper panel 
pie-charts, left for CRC and right for CRC-LM). This 
result highlighted the efficiency of the EXPEL method in 
collecting soluble and accessible proteins. Along with the 
subcellular localisation we further focused on investigating 
the pathways that could be altered by the modulated 
proteins identified in EXPEL fluids from colon and liver 
patients. To this end, we employed Ingenuity Pathway 
Analysis tool. The top modulated pathways are shown in 
Figure 2B (left for CRC and right for CRC-LM) and can 
be grouped into 3 main classes i) inflammatory response, 
ii) cytoskeleton reorganisation and iii) metabolism. These 
3 classes are well-recognised cancer hallmarks. Following 
the analysis of differentially expressed proteins, we 
have examined their expression level in normal healthy 
tissues. This was done at the mRNA level by interrogating 
BioGPS public database (Figure 2C, left for CRC and 
right for CRC-LM). By applying the following criteria, 
candidate biomarkers could ideally be selected: i) proteins 
uniquely expressed or consistently overexpressed in the 
tumour compared to the paired normal tissue, ii) proteins 
located in the extracellular space and likely to be found 
in liquid biopsies, particularly plasma, and iii) proteins 
not or expressed at low levels in normal tissues. Based on 
these criteria, we have listed in Supplementary Table 3 (for 
CRC) and Supplementary Table 4 (for CRC-LM), the most 
promising candidates that deserve future validation tests.
EXPEL-extruded fluid contains exosomes and 
miRNAs
Several experimental evidences point at exosomal 
proteins and microRNAs (miRNAs) as promising 
sources of novel biomarkers for clinical diagnosis [12, 
13]. Therefore, we asked the question whether EXPEL-
extruded fluid could contain exosomes and whether the 
detection of miRNAs would be possible. We have first 
attempted to isolate exosomes from EXPEL-extruded 
fluids of 3 CRC-LM biopsies and their normal counterparts 
using serial ultracentrifugations. Dynamic light scattering 
of the isolated vesicles revealed that their average diameter 
was in the size range expected for exosomes (Figure 3A). 
To further validate these exosomal preparations, the 
corresponding protein extracts were resolved by SDS-
PAGE. CD9 and CD63 known exosomal markers and 
GRP78, a protein of the endoplasmic reticulum, were 
used as controls for exosomes isolation and to exclude 
presence of contaminating organelles (Figure 3B). We 
further confirmed the presence of exosomes in EXPEL-
derived preparations by transmission electron microscopy. 
As shown in Figure 3C, the preparations evidenced 
many vesicles of different sizes, including vesicles with 
a diameter of less than 100 nm that should correspond 
to exosomes. Immunogold labeling using anti-CD63 
confirmed the presence of exosomes in EXPEL-extruded 
fluid (Figure 3D).
Encouraged by these findings we next sought to 
verify whether miRNAs could be detected in EXPEL-
extruded fluid. For this purpose, we have isolated RNA 
from 3 colorectal cancer patients and their corresponding 
normal tissues. As shown in Figure 3E, EXPEL-extruded 
fluids allowed the identification and quantification of a 
discrete panel of cancer-related miRNAs. The differential 
analysis indicated that many of them were overexpressed 
in the cancerous lesions by comparison with the normal 
counterparts and thus could be of particular interest. To 
further validate our findings and in order to translate our 
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Figure 1: EXPEL method does not alter tissue morphology and antigenicity. (A) Schematic overview of EXPEL workflow. 
Diagram of standard tissue processing from the surgery room to pathologists. EXPEL extruded fluid obtained within 3 minutes from a tissue 
sample, is prepared for the indicated applications or stored at −20°C. (B) Colorectal primary tumors (n=10, left panel) and liver metastases 
(n=10, right panel) were subjected to clinical routine analysis and EXPEL method followed by hematoxylin/eosin (H&E) staining and 
immunolabelling of the indicated markers (representative pictures are shown for 3 patients). The quantitative evaluation for each marker 
was assessed as outlined in the Material and Methods section. The error bars indicate standard deviation of means. Images of representative 
fields were taken at 100× magnification.
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results in a clinical setting, we next verified the expression 
of 8 selected miRNAs (miR-146b-5p, miR-183-5p, miR-
132-3p, miR-29a-3p, miR-15-5p, miR-21-5p, miR-29b-
3p, miR-203a-3p) in colorectal cancer patient and healthy 
donor sera. As shown in Figure 3F, all the miRNAs tested 
could be amplified by qRT-PCR, therefore rendering 
the data obtained using EXPEL-extruded fluids readily 
translatable in a clinical context. Moreover, among the 
Figure 2: Proteomic analysis of EXPEL extruded fluid identifies potential cancer biomarkers. (A) Absolute numbers 
of proteins, identified after proteomic analysis of EXPEL extruded fluids, in at least 4 out of 7 for CRC (upper, left panel) and 3 out of 
6 for CRC-LM (upper right, panel) replicates. Pie charts indicating the predicted sub-cellular localization of identified proteins for CRC 
(on left side) and CRC-LM (on right side) are shown. (B) Significantly altered canonical pathways of cancer up-regulated and uniquely 
expressed proteins analyzed by the IPA software using IPA Core Analysis for colon (on the left) and liver (on the right) EXPEL extruded 
fluids. The canonical pathways are shown along the y-axis of the bar chart. The x-axis indicates the statistical significance (on the upper 
part, calculated using the right-tailed Fisher exact test. The P value indicates which biologic annotations are significantly associated with 
the input molecules relative to all functionally characterized mammalian molecules. “Ratio” (differential yellow line and markers) refers to 
the number of molecules from the dataset that map to the pathway listed divided by the total number of molecules that map to the canonical 
pathway from within the IPA knowledgebase. (C) Normal tissue gene expression of potential biomarkers candidates discovered from 
colorectal cancer (left panel) and liver metastases (right panel). mRNA expressions were assessed using BioGPS public database.
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amplified miRNAs, we found that miR-183-5p, miR-
132-3p, miR-21-5p, miR-29b-3p, miR-203a-3p were 
significantly overexpressed in CRC patients compared 
to healthy donor sera. Further analyses are suggested 
to assess the use of these miRNAs as signature holding 
diagnostic potential in the context of CRC.
Figure 3: EXPEL extruded fluid contains exosomes and miRNAs readily detectable in patients sera. (A) Dynamic light 
scattering of isolated exosomes from normal and tumoral samples revealed that the average diameter of the vesicles is in the expected size 
range, a representative image of three independent experiment is shown. (B) Western blot validation of exosomal preparations. CD9 and 
CD63 are used as positive control for exosomes isolation whereas GRP78 is employed as control to exclude the presence of contaminating 
organelles. (C) Electron microscopy revealed the presence of exosomes (black arrows) in EXPEL extruded fluid. A representative image 
of two independent experiments is shown. (D) A representative picture of anti-CD63 immunogold labeling evidencing specific staining for 
exosomal vesicles in normal and tumoral samples. (E) miRNome analysis of 84 different miRNAs in EXPEL extruded fluid. The amplified 
miRNAs are shown in heat maps indicating fold-change differences in tumoral samples versus their normal counterpart (FC T/N). Samples 
analyzed correspond to a pool of 3 EXPEL extruded fluids from CRC and 3 of their matched normal counterparts. (F) Validation of the 
indicated miRNAs in serum samples of healthy donors (CTRL, n=11) and CRC patients (n=13). Error bars indicate standard deviation of 
means. Statistical analysis was performed using Whitney U test (* p<0.05, ** p<0.01 and *** p<0.001).
Oncotarget10671www.impactjournals.com/oncotarget
EXPEL-extruded fluid contains tumour DNA
Tumour DNA (tDNA) is routinely used as a 
biomarker for diagnosis and therapy selection in cancer 
patients [14, 15]. In the clinics, tDNA is extracted from 
paraffin sections (FFPE) through complex workflow, 
often yielding small DNA quantities of poor quality. 
We first examined the possibility that EXPEL-extruded 
fluids could serve as a source of tDNA and then whether 
EXPEL tDNA would be comparable in terms of yield and 
quality to FFPE tDNA. We determined the amounts of 
FFPE and EXPEL tDNAs from 20 CRC tumour samples 
including 10 primary lesions and 10 CRC-liver metastases. 
tDNA was extracted from 20 FFPE slides, according to a 
routine molecular genetics laboratory protocol (University 
Hospital of Liège, Belgium) and from a volume of 250 μL 
of EXPEL-extruded fluid, as described in the Material and 
Methods section. Under these experimental conditions, we 
found that the yield of extracted DNA was comparable 
between FFPE and EXPEL samples (Figure 4A, left 
panel). Knowing that poor DNA quality mainly has an 
effect on the amplification of long targets, we next assessed 
the relative quality of FFPE and EXPEL DNA extracts by 
normalising 129bp- and 305 bp-fragment concentrations 
against the concentration obtained for 41 bp-fragments 
(Figure 4A, middle and right panels, respectively). The 
ratios of long to short fragments indicated that tDNA 
extracted from EXPEL fluids presented with significantly 
better quality (ratios close to 1) in comparison with the 
tDNA derived from FFPE samples.
Encouraged by these promising results, we next 
sought to determine if molecular biology tests used in 
routine CRC diagnostics would match between FFPE 
and EXPEL tDNA extracts. Nowadays, microsatellite 
instability (MSI) testing in predicting prognosis and 
response to chemotherapeutic agents in CRCs is widely 
used [16]. As shown in Figure 4B (left panel), on a 
representative case, the MSI-PCR electropherograms at 5 
loci (NR-27, NR-21, NR- 24, BAT-25 and BAT-26), were 
comparable between FFPE and EXPEL tDNAs. All other 
samples analysed showed concordant MSI positive or 
negative status (Figure 4B, right panel).
Characterising genomic aberrations in tumours – for 
diagnosis, therapeutic decisions, and prognostic purposes 
– using genome-sequencing techniques has become an 
integral part of the current precision medicine approach 
[17]. The use of pyrosequencing analysis of KRAS 
mutational status confirmed the fidelity of EXPEL in 
comparison to FFPE tDNA extracts, when we searched for 
codon 12 KRAS mutation (Figure 4C). Next-generation 
sequencing (NGS) technology has revolutionised the 
discovery of genetitc markers in cancer research. Soon, 
NGS will undoubtedly occupy a central position in routine 
molecular screening of tumours in diagnostic laboratories 
[18, 19]. Therefore, we next sought to determine whether 
EXPEL tDNA would be suitable for NGS analysis. As 
shown in Figure 4D, NGS data obtained for 10 clinically 
relevant genes using EXPEL tDNA, were fully concordant 
with those obtained using FFPE tDNA.
EXPEL-extruded fluids are a rich source of 
metabolites
Considering that cells excrete metabolic byproducts 
for detoxification and communication purposes [20], 
and that research is increasingly addressing efforts in 
cancer metabolome studies as source of biomarkers, we 
sought to verify whether EXPEL-extruded fluids could 
be rich in metabolites. Starting from EXPEL-extruded 
fluid, we have enriched water-soluble metabolites 
and fatty acid mediators and analysed those using the 
UPLC-MS (multiple reaction monitoring) approach. As 
shown in Figure 5A, metabolomic analysis of EXPEL-
extruded fluids from both CRC (on the left) and CRC-
LM (on the right) allowed a comprehensive detection and 
quantification of a range of metabolites in pathological 
samples. In addition, the differential analysis of 
tumoural samples versus corresponding normal adjacent 
tissues evidenced a cluster of significantly modulated 
metabolites, which were detected consistently across all 
samples (Figure 5B, left for CRC and right for CRC-
LM). Among others, elevated levels of succinic acid, 
S-adenosylhomocysteine and adenylsuccinic acid were 
readily detected for what concern CRC while arginine 
was the most abundant metabolite found in the CRC-
LM patients. The metabolites consistently upregulated 
in CRC and CRC-LM analyses were further examined 
using MetaboAnalyst (www.metaboanalyst.ca). In 
Supplementary Figure 3 ((A) for CRC and (B) for CRC-
LM) are highlighted the metabolic pathways altered in 
relation to the queried metabolites. Interestingly, we 
noticed a low level of overlap among the most impacted 
metabolic pathways between CRC and CRC-LM analyses. 
This might reflect a potential metabolic reprogramming 
that occurred during liver metastases dissemination. Along 
with the analysis of general metabolites, EXPEL-extruded 
fluids were further used to perform lipidomic profiling. 
Lipidomic hierarchical clustering analysis followed by 
Pearson Correlation is shown in Supplementary Figure 4 
((A) left for CRC and panel for CRC-LM) together with 
the top 20 up- and down- modulated lipid mediators ((B) 
left for CRC and panel for CRC-LM).
DISCUSSION
Biomarker discovery is a crucial step for cancer 
early diagnosis, prognosis and prediction of therapy 
response. Advances in precision medicine have improved 
the clinical management of cancer resulting into a 
better patient clinical outcome while lowering the risks 
associated to drug toxicity. However, to this day, the 
identification of new clinically relevant biomarkers for 
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early diagnosis remains disappointing. The traditional 
approach for biomarker discovery based on a single or a 
few molecules needs to be revised since it has been shown 
to be inefficient for complex malignancies like cancer.
In this study, we present EXPEL as a new method 
for the isolation of molecular species such as proteins, 
non-coding regulatory RNAs, DNA and metabolites that 
represent the fundamental material for both researchers 
Figure 4: EXPEL extruded fluid contains high quality tumor DNA (tDNA) that is exploitable for genetic profiling. (A) 
Left panel, equivalent yield of tDNA was obtained from FFPE sections and matched EXPEL fluids of CRC primary lesions (n=10) and 
CRC-liver metastatic lesions (n=10). The quality of the DNA was assessed on the same extracts. The ratios of long 129bp (middle panel) 
and 305bp (right panel) to short amplified fragments (41bp) indicated that EXPEL tDNA presented with significantly higher amounts 
of long fragments in comparison with the FFPE tDNA. Dot plots show the mean ± SEM. Statistical significance was calculated using 
Wilcoxon paired test (* p<0.05, ** p<0.01 and *** p<0.001). (B) PCR microsatellite instability (MSI) analysis at 5 loci (NR-27, NR-21, 
NR- 24, BAT-25 and BAT-26) of a representative CRC primary tumor shows similar electropherograms for both FFPE and EXPEL tDNA 
extracts (left panel). Right panel summarizes MSI analysis results obtained for a subset of 11 tumor samples. The corresponding MMR 
status, based on routine IHC detection of MMR genes (MLH1, MSH2, MSH6, PMS2), is given. (C) Concordant KRAS mutational status 
(codon 12) detected using pyrosequencing on FFPE and EXPEL tDNAs isolated from CRC primary lesions and CRC-liver metastatic 
lesions. (D) Next-generation sequencing (NGS) technique used for the detection of 10 cancer related genetic alterations showed identical 
results on FFPE and EXPEL tDNAs isolated from CRC and CRC-LM lesions.
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Figure 5: Metabolomic profile of EXPEL extruded fluids from CRC and CRC-LM. (A) Pearson correlation clustering of 
general metabolites quantified in the EXPEL extruded fluids from CRC (on the left, n=13) and CRC-LM (on the right, n=9). The individual 
values are relative quantification ratios of CRC and CRC-LM versus their normal colon and liver adjacent tissues. (B) Top 10 up- and 
down- modulated metabolites are shown for CRC (on the left) and CRC-LM (on the right) EXPEL extruded fluids. Error bars indicate 
standard error of means.
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and clinicians. The key features of EXPEL include: 
(a) the simplicity and rapidity of the procedure and its 
applicability to any tissue regardless of size and origin 
at no cost; (b) the possibility to share even limited 
amounts of fresh biopsies between pathologists and 
researchers; (c) the isolation of diverse biomolecules 
from a single EXPEL-extruded fluid; (d) the lack of need 
for optimisation of standard extraction procedures for 
biomolecules; and (e) the possibility to have long term 
storage of large collections of frozen EXPEL-extruded 
fluids allowing their use for prospective follow up and 
retrospective studies.
This proof-of-concept study was performed on 
primary human colorectal cancer and colorectal cancer 
liver metastases. We have demonstrate that the EXPEL 
methodology leads to the identification of valuable subsets 
of proteins that could differentiate between cancerous 
and normal samples. Moreover, the identified modulated 
proteins were found as strictly linked to cancer disease, 
thus reducing the probability of obtaining false positive 
results in following validation steps. Future studies on 
large series of patients will contribute to validate any of 
these markers for a clinical use. Apart from proteomic 
analysis, we have expanded the potential applications of 
EXPEL-extruded fluids to other OMICs methodologies, 
including those that are very challenging in terms of 
quantity and quality of starting biological material, such as 
miRNome profiling or libraries construction for NGS. For 
all the applications tested EXPEL-extruded fluids enabled 
excellent performance and rendered trustable results. 
In addition, no pre-analytical workflow or purification 
steps were applied to EXPEL-extruded fluids before 
any of the analyses were performed. This aspect brings 
as significant advantage a reduced variability in the pre-
analytic workflow favouring more reproducible results 
among different laboratories. Blood-based test are able 
to improve patients management for deadly diseases as 
cancer. It is worth of note that the subset of biomolecules 
identified in EXPEL-extruded fluids are likely to be found 
in biological fluids such as serum or plasma. Our research 
demonstrated it, in the frame of miRNAs study where the 
identified overexpressed miRNAs were readily detectable 
in CRC patient sera.
Since the greatest benefits for patients are likely to 
be reached from the management of early stage disease 
rather than from treatment of late stage disease, the access 
to precancerous lesions is essential. However, the clinical 
workflow imposes that such samples are not shared for 
research purposes and it directs the researchers towards 
using residual human material. This practice introduces 
a sampling bias that is likely to impact on the discovery 
of clinically qualified biomarkers for cancer diagnosis, 
prognosis and therapy. Moreover, considering that 
intratumour heterogeneity has major consequences on 
treatment design [21], it is critical to perform OMICs 
analyses and studies on a single tumoural region. To 
date, and to our knowledge, EXPEL is the first method 
that enables the simultaneous investigation of wide subset 
of biomolecules while allowing clinicians and scientists 
to work in synergy. As such, EXPEL is a timely needed 
method for systematic sample preparation to acquire high 
quality catalogues of data following OMICs explorations.
We believe that the EXPEL method opens a new era 
for biomarkers discovery and will have a major impact 
on translational research. We trust that this method meets 
the emerging concept of precision medicine where cancer 




The ethical committee of the University Hospital 
of Liege has approved the use of human material in 
the current study. All fresh and formalin fixed paraffin 
embedded (FFPE) primary colorectal cancer (CRC) 
and colorectal liver metastases (CRC-LM) samples 
were obtained from the institutional Biobank of the 
University Hospital of Liege, Belgium. According to 
Belgian law, informed consent was obtained using the 
opting-out procedure. Following surgical resection, the 
specimen was immediately transferred to the pathology 
department where a representative part of the lesion was 
excised together with the normal counterpart. EXPEL 
procedure was then applied as described below (Figure 
1A). At the end of the procedure the biopsies were fixed 
in formalin overnight and paraffin-embedded blocks were 
made for histological evaluations. Serum samples from 
normal healthy donors and colorectal cancer patients 
were obtained from the Department of Gastroenterology, 
University Hospital Liege. Clinical characteristics of 
individual patients involved in the current study are 
outlined in Supplementary Table 1 (for tissues) and 
Supplementary Table 2 (for sera).
EXPEL-extruded tissue fluids
Fresh surgical biopsies were collected immediately 
after surgery, cut into 3 mm3 pieces and placed in a 10 mL 
plastic syringe (Cat.: # 302188, BD Plastipak™ Madrid, 
Spain). One mL of hypertonic extraction buffer (PBS 
supplemented with NaCl, 4.5 g in 500 mL) was added into 
the syringe together with the sample. The plunger was then 
moved to 5 mL mark, allowing an intake of approximately 4 
mL of air-bubble between the plunger and the liquid surface. 
Following this the tissue was subjected to an alternating 
pressure for 1 min, by moving the plunger from 5 mL to 
2.5 mL. Separate measurements with attached manometer 
showed that the effective pressure ranged between 1.2 bar 
(compressed state) to 0.8 bar (relaxed state) and 1 bar at 
(initial condition, plunger at 5 mL mark). The procedure 
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was repeated for a total of three times for each sample. 
EXPEL-extruded tissue fluids were pooled and stored at 
−20°C. The whole procedure is completed in 3 min and the 
EXPEL processed tissue sample can re-enter the classical 
tissue processing for clinical evaluation.
Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded tissue sections 
were prepared from primary colon tumours, adjacent 
normal colon as well as from colon cancer liver metastases 
and their normal liver counterpart. Tissue samples were 
sliced from paraffin blocks (5 μm sections), deparaffinated 
3 times in xylene for 5 min and hydrated in methanol 
gradient (100%, 95%, 70%, and 50%). Blocking of 
nonspecific peroxidase activity was conducted for 30 
minutes in 3% H2O2 and 90% methanol. Following this, 
specimens were first subjected to antigen retrieval in 
citrate buffer (10 mM, pH 6, 95 ºC for 45 min) and then 
blocked in 1.5% normal serum (Vector Laboratories, 
Burlingame, CA, USA). Tissues were immunostained 
using following antibodies: CEA (1:8000; Cat.: # 
GA52661, Dako, Glostrup, Denmark), Ki67 (Cat.: # 
790-4286, Ventana Roche, Tucson, AZ, USA), EpCam 
(Cat.: # 760-4383, Ventana Roche), MLH1 (Cat.: # 790-
4535, Ventana Roche), MSH2 (Cat.: # 760-4265, Ventana 
Roche), MSH6 (Cat.: # 790-4455, Ventana Roche), PMS2 
(Cat.:# 760-4531 Ventana Roche). All antibodies were 
incubated overnight at 4°C. The samples were then washed 
in PBS and incubated for 30 minutes with biotinylated 
secondary antibodies (Vector Laboratories, Burlingame, 
CA, USA). The signal was revealed using avidin-biotin-
complex kit (Vectastain ABC kit, Vector Laboratories, 
Burlingame, CA, USA) and 3,3′-diaminobenzidine 
tetrachlorhydrate dihydrate (DAB) in 5% H2O2. The 
tissues were counter-stained with hematoxylin. IHC 
scoring was performed by three independent pathologists 
(EM, JB and PD). Each IHC slide was assessed for the 
intensity of the staining using the following scale: 0 = 
no staining, 1 = weak, 2 = moderate and 3 = strong. The 
tissues were further evaluated for the extent of positivity 
using the scale: 1 = 0-33%, 2 = 33-66%, 3 = 66-100%. The 
values obtained by each of the two scales were multiplied 
to yield a composite value called IHC score.
Proteomic analysis
Protein quantification of EXPEL-extruded fluids 
was performed using BCA quantification Kit (Cat.: # 
23225, Pierce, Thermo Scientific, Rockford, IL, USA). A 
volume corresponding to 6 μg of proteins was lyophilised 
and re-suspended in 50 μL of RapiGest SF surfactant 
(Cat.: # 186001861, Waters, Waters Corporation, 34 Maple 
Street, Milford, MA 01757). The samples were incubated 
for 10 minutes at 90°C. Proteins were further reduced in 
1,4-dithiothreitol (10 mM) (Cat.: # D0632-10G, Sigma-
Aldrich, St. Louis, MO, USA), for 30 minutes at 60°C and 
then alkylated using 2-chloroacetamide (22mM) (Cat.: # 
30208220, Sigma-Aldrich), for 30 minutes at RT and in 
darkness. Proteins digestion was conducted overnight at 
37°C with trypsin (Cat.: # 29341524, Promega, Madison, 
WI, USA) using a 1:50 enzyme to protein ratio. Following 
the digestion, 1μL of PNGase enzyme (Cat.: # P0704S, 
BioLabs, 240 County Road Ipswich, MA 01938-2723) 
was added to each preparation and samples were incubated 
at 37°C for 1h. Peptides were acidified with TFA, at final 
concentration of 0.5 %, for 1h at 37°C. Samples were 
further centrifuged at 13000 g for 10 minutes. After 
collecting the supernatant, peptides were desalted using 
ZipTip (Cat.: # ZTC18S096, Merck Darmstadt, Germany) 
according with the manufacturers protocol.
Peptide samples from liver metastases were analysed 
using 2D-LC-MS/MS analysis, while colorectal samples 
were analysed using 1D-LC-MS/MS analysis. Before 
analysis, each sample was spiked with a commercial 
mixture of protein digest standards originated from non-
human biological material: the MassPREP™ Digestion 
Standards (Waters, Corp., Milford, USA), at 100 and 150 
fmol of yeast alcohol dehydrogenase (ADH) for CRC 
and CRC-LM per sample, respectively. The commercial 
standard consists of two standard mixtures (MPDS Mix 
1 and MPDS Mix 2) containing protein digests of ADH, 
rabbit glycogen phosphorylase b, bovine serum albumin 
and yeast enolase at different protein ratios.
Proteomic analysis of colorectal cancer
one μg of desalted peptides were injected on an 
Acquity M-Class UPLC (Waters, Milford, MA, USA) 
connected to a Q Exactive Plus (Thermo Scientific, Bremen, 
Germany), in nano-electrospray positive ion mode. The 
samples were loaded on the trap column (Symmetry C18 
5μm, 180 μm × 20 mm, Waters) in 100% solvent A (water 
0.1% formic acid) during 3 minutes and subsequently 
separated on the analytical column (HSS T3 C18 1.8 μm, 
75 μm × 250 mm, Waters); flow rate 600 nL/min, solvent 
A (0.1% formic acid in water) and solvent B (0.1% formic 
acid in acetonitrile), linear gradient 0 min, 98% A; 5 min, 
93% A; 135 min, 70% A; 150 min, 60% A, total run time 
was 180 min. The MS acquisition was conducted in data-
dependent mode. The parameters for MS acquisition were: 
MS range from 400 to 1750 m/z, Resolution of 70,000, 
AGC target of 1e6 or maximum injection time of 50 ms. 
The parameters for MS2 spectrum acquisition were: 
isolation window of 2.0 m/z, normalised collision energy 
(NCE) of 25, resolution of 17500, AGC target of 1e5 or 
maximum injection time of 50 ms, under fill ratio of 1.0%.
Proteomic analysis of liver metastases
Three μg of peptides were injected onto the 
2D-nanoAquity UPLC (Waters, Corp., Milford, USA) 
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coupled online with a Q-Exactive mass spectrometer 
(Thermo Scientific), operated in nano-electrospray 
positive ion mode. The 2D-nanoUPLC system consisted 
of a reversed phase operated at pH 10 and a reversed phase 
operated at pH 3. The samples were loaded at 2 μL/min 
(20 mM ammonium formate solution adjusted to pH 10) 
on the first column (X-Bridge BEH C18 5 μm (300 μm × 
50 mm, Waters)) and subsequently eluted in three steps of 
acetonitrile gradient (13.3%, 19% and 65%). Each eluted 
fraction was desalted on the trap column (Symmetry 
C18 5μm (180 μm × 20 mm, Waters)) with previous 
10X online dilution to pH 3. The individual fractions 
were subsequently separated on the analytical column 
(BEH C18 1.7 μm (75 μm × 250 mm, Waters)) operated 
at 250 nL/min. The gradient was composed of solvent A 
(0.1% formic acid in water) and solvent B (0.1% formic 
acid in acetonitrile) as follows: 0 min, 99% A; 5 min, 
93% A; 140 min, 65% A. The total run time of each step 
was 180 min. The mass spectrometer method is a TopN-
MSMS method where N was set to 12, meaning that the 
spectrometer acquires one Full MS spectrum, selects the 
12 most intense peaks in this spectrum (singly charged 
precursors excluded) and makes a full MS2 spectrum 
of each of these 12 compounds. The parameters for MS 
spectrum acquisition were: mass range from 400 to 1750 
m/z, resolution at 70000, AGC target of 1e6 or maximum 
injection time of 200 ms. The parameters for MS2 
spectrum acquisition were: isolation window of 2.0 m/z, 
collision energy of 25, resolution of 17500, AGC target of 
1e5 or maximum injection time of 50 ms.
Proteomic data analysis
Raw MS files were analysed by MaxQuant Software 
(version 1.5.2.8, Max Planck Institute of Biochemistry, 
Martinsried, Germany). MS/MS spectra were searched 
against Uniprot human database by the Andromeda 
search engine. Normalisation of the data was done using 
LFQ algorithm [22]. Carbamidomethyl (C) was set as a 
fixed modification, while oxidation of methionine and 
deammidation of Asn to Asp residues were used as variable 
modifications for all searches. Detection of minimum 
two peptides was required for protein identification. The 
false discovery rate (FDR) was set to 0.01 on the protein 
and on the peptide levels. The main search tolerance was 
set at 5 ppm (10 ppm for MS/MS). Additional protein 
information, such as subcellular localisation, biological 
functions were determined using gene ontology annotation 
available on Uniprot (www.uniprot.org), STRING version 
10 (www.string-db.org) and ExoCarta (www.exocarta.
org). Gene expression level of potential biomarker 
candidates in healthy human tissues was assessed through 
BioGPS public mRNA database (www.biogps.org). 
Pathway analysis of modulated proteins was performed 
using Ingenuity Pathways Analysis (IPA; Version 8.5; 
www.ingenuity.com), aberrant functional networks 
and canonical pathways were recognised. The P value 
associated with a function or a pathway is a measure of the 
likelihood that the association between a set of focus genes 
in the experiment and a given process or pathway is the 
result of random chance; in general, a P value (calculated 
using the right-tailed Fisher exact test) <0.05 indicates a 
statistically significant, non random association.
The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository with the dataset identifier 
PXD005693 and PXD005709 for CRC and CRC-LM, 
respectively.
Metabolomic analysis of EXPEL-extruded fluid
One mL of methanol (Wako, Tokyo, Japan) was 
added to 200 μL of EXPEL-extruded fluid. Sampled 
were then sonicated and split into two separate vials, 
each containing 0.6 mL of initial solution: i) GM (general 
metabolites) and ii) LM (lipid mediators). Description of 
further sample processing was outlined elsewhere [23]. 
MS data acquisition was performed on UPLC coupled 
to triple-quadrupole MS (LCMS-8050; Shimadzu, 
Kyoto, Japan), according to manufacturer instructions 
for analysing Primary Metabolites version 2.0 (Cat.: # 
225-24865A, Shimadzu) and Lipid Mediators version 2.0 
(Cat.: # 225-24873A, Shimadzu). Peak areas of individual 
metabolites were normalised against the spiked internal 
standards and then uploaded in the Multi Experiment 
Viewer software version 4.8 [24] and subjected to Pearson 
correlation clustering.
Exosomes isolation from EXPEL-extruded fluid
Exosomes were isolated from EXPEL-extruded 
fluids using differential ultracentrifugation as previously 
described [25]. Briefly, fresh EXPEL-extruded fluids of 
colorectal cancer liver metastasis and normal adjacent 
liver were filtered (0.22 μm filter) to remove debris. The 
filtered fluids were then ultracentrifuged for 2 hours at 
100000 g (SW-28 rotor, Optima LE80 ultracentrifuge, 
Beckman Coulter, Brea, CA, USA). The exosome pellets 
were washed once with PBS, centrifuged again for 2 hours 
at 100000 g and finally suspended in 80 μl PBS. Sample 
quality was assessed from 5 μl by dynamic light scattering 
with Zetasizer Nano ZS (Malvern Instruments, Ltd., 
Worcestershire, UK). Remaining sample was used for 
transmission electron microscopy analysis or western-blot 
protein detection. Proteins were isolated from exosome 
suspensions with 1% SDS lysing buffer supplemented 
with protease and phosphatase inhibitors. Protein 
concentration was assessed by bicinchoninic acid assay 
(Cat.: # 23225; Pierce, Rockford, IL, USA). Labeling of 
exosomes for quality control purposes was performed as 
previously described [26]. Briefly, exosomes adsorbed on 
formvar-carbon coated grids were successively washed, 
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fixed in 2% formaldehyde and incubated for 2 hours at 
RT with primary anti-CD63 antibody (Cat.: # ab124045, 
Abcam) diluted 1/20 in PBS-BSA (0.2%) supplemented 
with normal goat serum (1/50) and 1 hour at RT with 
gold-conjugated secondary anti-rabbit antibody (Aurion, 
Wageningen, The Netherlands) diluted 1/40 in PBS-BSA 
(0.2%, pH 8.2). Samples were postfixed for 10 minutes in 
2.5% glutaraldehyde and contrasted using uranyl acetate 
and lead citrate. Pictures were made with a Jeol JEM-1400 
transmission electron microscope at 80 kV (Jeol, Peabody, 
MA, USA).
miRNA isolation, miRNome profile and qPCR 
from EXPEL-extruded fluid
RNA was isolated from EXPEL-extruded fluids 
and human sera using miRNeasy Serum/Plasmakit (Cat.: 
# 217184, Qiagen, Hilden, Germany), according to the 
manufacturer protocol. Before extraction, C. elegans 
miR-39 (Cat.: # 219610, Qiagen) was spiked in each 
individual sample (1.6 × 108 copies/μL) as internal control. 
For miRNome profiling (discovery), the extracted RNA 
from 3 colorectal patients were pooled to have one sample 
for the tumoural and one sample for normal tissues. For 
targeted qPCR (validation) all patient sera were processed 
individually. In both cases, 5 μL of RNA were used as 
template for a RT reaction using miScriptII RT kit (Cat.: 
# 218161, Qiagen) according with manufacturer protocol. 
The cDNA was further diluted 1:5 in RNase-free water 
and 5 μL of diluted samples were used as template for the 
pre-amplification reaction using miScript PreAMP PCR 
Kit (Cat.: # 331452, Qiagen). For the pre-amplification 
reaction for EXPEL and sera samples, miScript PreAMP 
Pathway Primer Mix (Cat.: # 331241, Qiagen) and a 
mix of the primers listed below were used according 
with manufacturer’s protocol. Preamplified samples 
were diluted 1:20 in RNase-free water (except from the 
normal colon sample that was used undiluted). EXPEL-
extruded fluid samples were used for miRNome analysis 
using miScript miRNA PCR Array (Human Cancer 
PathwayFinder Cat.: # 331221), while the sera samples 
were checked for the miRNAs listed in the table below. 
All qPCRs were done using miScript SYBR Green PCR 
Kit (Cat.: # 218073, Qiagen) according to manufacturer 
instructions.
DNA isolation from EXPEL-extruded fluid
DNA was isolated from EXPEL-extruded fluid 
and paraffin embedded sections from colorectal cancer 
tumours and liver metastasis samples. Briefly, DNA 
was extracted from 250 μl of EXPEL-extruded fluids 
using the QIAamp Circulating Nucleic Acid Kit (Cat.: # 
55114, Qiagen) following the manufacturer’s protocol. 
FFPE tissues were cut in 4 μm sections and mounted 
on glass slides. In order to maximise tumoural content, 
cancerous tissues areas were defined by a pathologist and 
manually macro-dissected from 20 tissue slides. DNA 
extraction was then obtained using an AllPrep DNA/RNA 
FFPE extraction kit (Cat.: # 80234, Qiagen) according to 
manufacturer’s protocol.
Microsatellite instability
DNA was extracted from a subset of FFPE samples 
and their corresponding EXPEL-extruded fluids as 
described above. MSI-PCR testing was performed using 
multiplex PCR assay comprising 5 quasimonomorphic 
mononucleotide repeats (BAT-26, BAT-25, NR-21, 
NR-22 and NR-24) as previously described [27]. 
Samples demonstrating instability for at least 3 of the 5 
mononucleotide markers evaluated were considered as 
MSI positive. Known MSI positive and negative DNA 
samples were tested in parallel as controls.
PCR for DNA quantification and quality 
assessment
Absolute DNA quantification and quality 
assessment based on qPCR experiments were performed 












using the LightCycler480 qPCR machine (Roche 
Diagnostics) and KAPA hgDNA Quantification and QC 
Kit (Cat.: # KK4963, Sopachem, Belgium) according to 
the manufacturer’s protocol. Briefly, a pre-diluted set of 
DNA standards and primer targeting different portions of 
a highly conserved single-copy human locus are amplified 
in an optimised SYBR Green I-based qPCR. Absolute 
quantification is achieved with the primer pair defining the 
shortest fragment (41bp), whereas the additional primers 
amplifying 129bp and 305bp fragments are used to derive 
information about the amount of amplifiable template in 
the DNA sample. Since poor DNA quality has a greater 
impact on the amplification of longer targets, the relative 
quality of a DNA sample can be inferred by normalising 
the concentration obtained using the 129 bp or 305 bp 
assay against the concentration obtained from the 41 bp 
assay.
Pyrosequencing analysis
DNA was extracted from a subset of FFPE 
samples and their corresponding EXPEL-extruded fluids 
as described above. PCR and pyrosequencing were 
performed for KRAS codon 12 region as previously 
described [28].
Next-generation sequencing
DNA was extracted from FFPE samples and their 
corresponding EXPEL-extruded fluids as described 
above. The indicated regions of interest were amplified 
using a laboratory developed multiplex PCR using Qiagen 
multiplex PCR plus kit (Qiagen). Molecular barcoding was 
performed with ‘MID for Illumina Miseq’ (Multiplicom, 
Belgium) according to the manufacturer’s protocol. PCR 
products of each patient were the pooled and purified 
using Agencourt AMPure XP beads (Beckman Coulter, 
USA). Each patient library was then quantified using 
‘Quanti-it Picogreen dsDNA Assay Kit’ (Fisher Scientific, 
USA) and the Fluostar Optima System (BMG Labtech, 
Germany). Equimolar amounts of each patient PCR 
products were then pooled to obtain the final library. The 
library was then quantified and denatured according to 
the standard Illumina’s MiSeq protocol. Sequencing was 
performed with a MiSeq v2 cartridge with 500 cycles 
(Illumina, USA). Alignment of the fastq files and variant 
calling were made using SeqNext Version 4.1.1 build 511 
(JSI medical systems, Germany).
Statistical analysis
Data were analysed using the GraphPad Prism 
4 software program. For miRNA studies statistical 
significance of the expression was assessed using Mann–
Whitney U-test. tDNA results were analysed according 
with Wilcoxon paired test. A value of P≤ 0.05 was 
considered to be significant.
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